Design and functional characterization of a first-in-class irreversible inhibitor of HOIL-1-interacting protein (HOIP) with selective antitumor activity against B-cell non-Hodgkin lymphoma

G. Gorjon de Pablo; A. M. Montagut; M. Armengol; L. Combes-Soia; O. Burlet-Schiltz; N. Profitos-Peleja; M. Fernandez-Serrano; J. Farres; P. G. Lutz; R. Estrada-Tejedor; J. I. Borrell; G. Roue

doi:10.1016/j.ejca.2024.114881

Design and functional characterization of a first-in-class irreversible inhibitor of HOIL-1-interacting protein (HOIP) with selective antitumor activity against B-cell non-Hodgkin lymphoma

G. Gorjon de Pablo
, A. M. Montagut
, M. Armengol
, L. Combes-Soia
, O. Burlet-Schiltz
, N. Profitos-Peleja
, M. Fernandez-Serrano
, J. Farres
, P. G. Lutz
, R. Estrada-Tejedor
, J. I. Borrell
, G. Roue

Research output: Indexed journal article › Meeting Abstract › peer-review

Original language	English
Pages (from-to)	S139-S139
Number of pages	1
Journal	European Journal of Cancer
Volume	211
DOIs	https://doi.org/10.1016/j.ejca.2024.114881
Publication status	Published - Oct 2024
Event	36th European-Organisation-for-Research-and-Treatment-of-Cancer / National-Cancer-Institute / American-Association-for-Cancer-Research Symposium on Molecular Targets and Cancer Therapeutics (EORTC/NCI/AACR) - Barcelona, Spain Duration: 23 Oct 2024 → 25 Oct 2024

Access to Document

10.1016/j.ejca.2024.114881

Cite this

Gorjon de Pablo, G., Montagut, A. M., Armengol, M., Combes-Soia, L., Burlet-Schiltz, O., Profitos-Peleja, N., Fernandez-Serrano, M., Farres, J., Lutz, P. G., Estrada-Tejedor, R., Borrell, J. I., & Roue, G. (2024). Design and functional characterization of a first-in-class irreversible inhibitor of HOIL-1-interacting protein (HOIP) with selective antitumor activity against B-cell non-Hodgkin lymphoma. European Journal of Cancer, 211, S139-S139. https://doi.org/10.1016/j.ejca.2024.114881

@article{2ac7cd0646c94733b332f9e4444cbe42,

title = "Design and functional characterization of a first-in-class irreversible inhibitor of HOIL-1-interacting protein (HOIP) with selective antitumor activity against B-cell non-Hodgkin lymphoma",

author = "\{Gorjon de Pablo\}, G. and Montagut, \{A. M.\} and M. Armengol and L. Combes-Soia and O. Burlet-Schiltz and N. Profitos-Peleja and M. Fernandez-Serrano and J. Farres and Lutz, \{P. G.\} and R. Estrada-Tejedor and Borrell, \{J. I.\} and G. Roue",

year = "2024",

month = oct,

doi = "10.1016/j.ejca.2024.114881",

language = "English",

volume = "211",

pages = "S139--S139",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

note = "36th European-Organisation-for-Research-and-Treatment-of-Cancer / National-Cancer-Institute / American-Association-for-Cancer-Research Symposium on Molecular Targets and Cancer Therapeutics (EORTC/NCI/AACR) ; Conference date: 23-10-2024 Through 25-10-2024",

}

Gorjon de Pablo, G, Montagut, AM, Armengol, M, Combes-Soia, L, Burlet-Schiltz, O, Profitos-Peleja, N, Fernandez-Serrano, M, Farres, J, Lutz, PG, Estrada-Tejedor, R , Borrell, JI & Roue, G 2024, 'Design and functional characterization of a first-in-class irreversible inhibitor of HOIL-1-interacting protein (HOIP) with selective antitumor activity against B-cell non-Hodgkin lymphoma', European Journal of Cancer, vol. 211, pp. S139-S139. https://doi.org/10.1016/j.ejca.2024.114881

Design and functional characterization of a first-in-class irreversible inhibitor of HOIL-1-interacting protein (HOIP) with selective antitumor activity against B-cell non-Hodgkin lymphoma. / Gorjon de Pablo, G.; Montagut, A. M.; Armengol, M. et al.
In: European Journal of Cancer, Vol. 211, 10.2024, p. S139-S139.

Research output: Indexed journal article › Meeting Abstract › peer-review

TY - JOUR

T1 - Design and functional characterization of a first-in-class irreversible inhibitor of HOIL-1-interacting protein (HOIP) with selective antitumor activity against B-cell non-Hodgkin lymphoma

AU - Gorjon de Pablo, G.

AU - Montagut, A. M.

AU - Armengol, M.

AU - Combes-Soia, L.

AU - Burlet-Schiltz, O.

AU - Profitos-Peleja, N.

AU - Fernandez-Serrano, M.

AU - Farres, J.

AU - Lutz, P. G.

AU - Estrada-Tejedor, R.

AU - Borrell, J. I.

AU - Roue, G.

PY - 2024/10

Y1 - 2024/10

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_univeritat_ramon_llull&SrcAuth=WosAPI&KeyUT=WOS:001345547300353&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1016/j.ejca.2024.114881

DO - 10.1016/j.ejca.2024.114881

M3 - Meeting Abstract

SN - 0959-8049

VL - 211

SP - S139-S139

JO - European Journal of Cancer

JF - European Journal of Cancer

T2 - 36th European-Organisation-for-Research-and-Treatment-of-Cancer / National-Cancer-Institute / American-Association-for-Cancer-Research Symposium on Molecular Targets and Cancer Therapeutics (EORTC/NCI/AACR)

Y2 - 23 October 2024 through 25 October 2024

ER -

Gorjon de Pablo G, Montagut AM, Armengol M, Combes-Soia L, Burlet-Schiltz O, Profitos-Peleja N et al. Design and functional characterization of a first-in-class irreversible inhibitor of HOIL-1-interacting protein (HOIP) with selective antitumor activity against B-cell non-Hodgkin lymphoma. European Journal of Cancer. 2024 Oct;211:S139-S139. doi: 10.1016/j.ejca.2024.114881

Design and functional characterization of a first-in-class irreversible inhibitor of HOIL-1-interacting protein (HOIP) with selective antitumor activity against B-cell non-Hodgkin lymphoma

Access to Document

Other files and links

Cite this